Real-World Prostate Cancer Treatments Are Better Than Clinical Trial Results, Study Finds
/0 Comments/in Retrospective studies/by MaxEnzalutamide Boosts PSA Control in High-Risk Prostate Cancer: Insights from the EMBARK Trial
/0 Comments/in Post-hoc, Retrospective studies/by MaxNew Study Reveals Key Factors That Influence How Quickly Prostate Cancer Becomes Resistant to Hormone Therapy
/0 Comments/in Retrospective studies/by MaxASCO GU 2025: Continuous ADT Remains Superior to Intermittent Therapy in Metastatic Hormone-Sensitive Prostate Cancer
/0 Comments/in Retrospective studies/by MaxASCO GU 2025: Lu-PSMA Therapy Outperforms Cabazitaxel in Advanced Prostate Cancer, Real-World Evidence
/0 Comments/in Retrospective studies/by MaxUndetectable PSA Nadir Linked to Better Outcomes in Metastatic Hormone-Sensitive Prostate Cancer: Real-World Data from IRONMAN Registry
/0 Comments/in Retrospective studies/by MaxASCO GU 2025: Impact of Homologous Recombination Repair Alterations on Survival Outcomes in Metastatic Hormone-Sensitive Prostate Cancer (BRCA, ATM, CDK12,…)
/0 Comments/in Observational, Retrospective studies/by MaxASCO GU 2025: Darolutamide Triplet Therapy Outperforms Alternatives in Advanced Prostate Cancer
/0 Comments/in Retrospective studies/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ASCO 2025 ATM bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy castration-resistant prostate cancer CDK12 clinical trial clinical trials crispr CYP11A1 inhibitor darolutamide drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA nanotechnology olaparib oncolytic virus personalized medicine prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics
Latest Posts
- Newsletter 23/2025 June 8, 2025
- Protein Design Leaps Forward Thanks to AI June 5, 2025
- Phase 1 Trial of XL309: USP1 Inhibitor Targeting DNA Repair in Solid Tumors June 5, 2025
- UPDATE About ACE-232: Phase 1 Trial of a Novel CYP11A1 Inhibitor for mCRPC June 5, 2025